Acumen Pharmaceuticals, Inc.
ABOSNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ABOS. That does not mean none is planned.
Get an email about ABOS's next catalysts
Track Acumen Pharmaceuticals (ABOS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
How ABOS's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
sabirnetug | Phase 2 | Alzheimer Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Acumen Pharmaceuticals, Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in Acumen Pharmaceuticals, Inc.'s (ABOS) pipeline across Phase 2. Its lead program is sabirnetug (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Acumen Pharmaceuticals, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Acumen Pharmaceuticals, Inc. (ABOS) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ABOS biotech catalysts?β
Add ABOS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Acumen Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
